Browse PTPRC

Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein Membrane raft Note=Colocalized with DPP4 in membrane rafts.
Domain PF12567 Leukocyte receptor CD45
PF00041 Fibronectin type III domain
PF12453 Protein tyrosine phosphatase N terminal
PF00102 Protein-tyrosine phosphatase
Function

Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001911 negative regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0001915 negative regulation of T cell mediated cytotoxicity
GO:0001933 negative regulation of protein phosphorylation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002250 adaptive immune response
GO:0002377 immunoglobulin production
GO:0002378 immunoglobulin biosynthetic process
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002710 negative regulation of T cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0006469 negative regulation of protein kinase activity
GO:0006470 protein dephosphorylation
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006929 substrate-dependent cell migration
GO:0006933 negative regulation of cell adhesion involved in substrate-bound cell migration
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0009615 response to virus
GO:0016311 dephosphorylation
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0030335 positive regulation of cell migration
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033673 negative regulation of kinase activity
GO:0033674 positive regulation of kinase activity
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0035701 hematopoietic stem cell migration
GO:0040017 positive regulation of locomotion
GO:0042098 T cell proliferation
GO:0042100 B cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0042326 negative regulation of phosphorylation
GO:0044770 cell cycle phase transition
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0046651 lymphocyte proliferation
GO:0048539 bone marrow development
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050777 negative regulation of immune response
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050857 positive regulation of antigen receptor-mediated signaling pathway
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051348 negative regulation of transferase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051607 defense response to virus
GO:0055074 calcium ion homeostasis
GO:0060348 bone development
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060759 regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0071593 lymphocyte aggregation
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098542 defense response to other organism
GO:1902656 calcium ion import into cytosol
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
GO:2000471 regulation of hematopoietic stem cell migration
GO:2000473 positive regulation of hematopoietic stem cell migration
GO:2000648 positive regulation of stem cell proliferation
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0005001 transmembrane receptor protein tyrosine phosphatase activity
GO:0016791 phosphatase activity
GO:0019198 transmembrane receptor protein phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0030055 cell-substrate junction
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
hsa04660 T cell receptor signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
R-HSA-416700: Other semaphorin interactions
R-HSA-202427: Phosphorylation of CD3 and TCR zeta chains
R-HSA-373755: Semaphorin interactions
R-HSA-202403: TCR signaling
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTPRC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTPRC and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18326813Acute Myeloid LeukemiaInhibit immunity (T cell function); immunotherapy targetSimultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML). We found that the anti-CD45 antibody, BC8, dose-dependently increased cytotoxicity induced by GO, and, to a lesser degree, free calicheamicin-gamma(1).
19332764Primary Cutaneous T-Cell Non-Hodgkin LymphomaPromote immunityRadioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) are limited. We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL. CD45 was highly expressed on hT-NHL patient samples (median, 2.3 x 10(5) antigen-binding capacity units/cell) and hT-NHL cell lines (3.4 x 10(5) CD45 antigen-binding capacity units/cell). These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients.
29606356hepatocellular carcinomaPromote immunity (T cell function); increase the efficacy of immunotherapyHere, we report one population of tumor-inducible, erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119+CD45-CD71+ phenotype.
15944250B16 Malignant MelanomaPromote immunityImmune activation in tumor-draining lymph nodes correlated with an increase in the number of CD45(+) cells infiltrating single dose irradiated tumors compared with nonirradiated mice.
18971421Nasopharyngeal CarcinomaInhibit immunity; Resistant to immunotherapyEight patients with recurrent NPC received CD45 mAbs followed by escalating doses of autologous EBV-specific CTL. Infusion of CD45 mAbs resulted in transient lymphopenia in all patients and an increase in interleukin-15 (IL-15) levels in 6 out 8 patients. All patients had an increase in their peripheral blood frequency of EBV-specific T cells after CTL infusion.
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTPRC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTPRC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0480.935
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4680.794
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.260.853
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1160.815
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3060.883
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6540.812
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7690.201
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2060.529
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3070.884
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4540.323
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5760.512
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0780.699
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTPRC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.110.20.91
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.418.2-2.81
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.311.1-5.80.642
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.221.4-15.20.315
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPRC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPRC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPRC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPRC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTPRC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTPRC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTPRC
Nameprotein tyrosine phosphatase, receptor type, C
Aliases T200; CD45; B220; CD45R; L-CA; LY5; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTPRC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.